Biotest : Speech of Peter Janssen - German Version

SPEECH BY PETER JANSSEN (CHAIRMAN OF THE MANAGEMENT BOARD) TO THE ANNUAL SHAREHOLDERS MEETING 2024 OF BIOTEST AG

7 May 2024

The spoken word counts!

1

Chart 1, cover picture:

Dear shareholders,

Dear members of the Supervisory Board,

Ladies and Gentlemen,

On behalf of myself, my colleague on the Management Board, Ainhoa Mendizabal Zubiaga, and my colleague on the Management Board, Dr Jörg Schüttrumpf, I would like to welcome you to this year's Annual General Meeting of Biotest AG. We are very pleased about your interest in Biotest and look forward to the personal dialogue with you today.

Ladies and gentlemen,

I would like to start by thanking you. It goes to my predecessor as CEO, Michael Ramroth. In his 20 years at Biotest, four of them as CEO, we have developed into a globally respected and successful pharmaceutical company with more than 2,600 employees and have opened

1. new chapter of profitable growth with our new, state-of-the-art Biotest Next Level production facility at the Dreieich site. For this, dear Michael Ramroth, we all owe you our thanks.

I myself got to know and appreciate him as a Management Board colleague in 2022. As the new Chairman of the Board of Management, in office since January 2024, I am now delighted to be able to present the report of the Board of Management to you for the first time at the Annual General Meeting of Biotest AG.

The motto of my presentation is: The time of harvest is about to begin at BNL, and we will be opening a new chapter for the company!

2

After years of high investments in the future, more and more pieces of the puzzle are currently coming together, which, with the start and ramp-up of production at Biotest Next Level, are increasingly forming an impressive whole. Thanks to our growth drivers Yimmugo and soon Albiomin and Fibrinogen and, with a time lag, Trimodulin, we can look forward to years of rising sales and profits and thus to the announced harvest for all of the company's key stakeholders.

We are opening a new chapter for Biotest by increasing the efficiency of the entire production process and boosting output. We are not only looking to the future with the further development of our products, but also with plant structure planning in order to set the course now for future growth at the Dreieich site. In addition, we are seeking partnerships not only with Grifols, but also with other market players.

Chart 2, Agenda:

You will now find out the details in my presentation. As usual, we will first take a look back at the highlights and key figures of the past financial year 2023. I will then explain our strategy and the transformation of Biotest into a high-growth company before we turn to the outlook and, finally, briefly address the important items on today's agenda.

3

Chart 3, cut-off page Highlights in the 2023 financial year:

As announced, I will begin with the most important topics that occupied us at Biotest in the 2023 financial year.

Chart 4, Progress in implementing our growth strategy 1:

The expansion of capacity for the production of Yimmugo and the further development of our portfolio have kept us busy at the new Biotest Next Level site throughout the year. The inspection by the US Food and Drug Administration (FDA) for the approval of Yimmugo in the USA was certainly an important milestone for our future.

4

The FDA's acceptance of our marketing authorisation application for Yimmugo in the USA was an important milestone in our intensive research and development efforts. We also reached the primary endpoint in the phase III trial for acquired fibrinogen deficiency. We have pushed ahead with the two ongoing phase III trials for our promising drug trimodulin. More on this later.

Chart 5, Progress in implementing our growth strategy 2:

The third core theme of our 2023 growth initiatives is the further expansion of our plasma collection stations to 36 by the end of 2023; there are already two more today. Last but not least, our increasingly close collaboration with our partner and main shareholder Grifols has proven to be very fruitful. Thanks to this successfully established partnership, we are able to produce our products worldwide and market them more easily.

5

Chart 6, Separation page key financial figures 2023:

We will now take a quick look at the key financial figures for the past financial year.

Chart 7, Revenue:

The impressive increase in turnover of around a third to € 685 million is primarily due to the proceeds from the sale of our technologies and development services to Grifols totalling € 190 million. Without this amount, Group sales would not have increased, in particular due to an IT disruption at the end of last year, which we coped with well but which nevertheless led to shifts in sales.

6

Chart 8, Result:

The turnaround to profitability is also largely due to the aforementioned technology disclosure totalling € 154 million and development work with Grifols. In addition, we were able to realise one-off income from the sale of Biotest subsidiaries to our main shareholder totalling € 23 million. After reporting a loss in the previous year, the annual earnings before interest and taxes of € 144 million are quite respectable. This means that we have achieved the EBIT forecast last issued.

7

Chart 9, Balance sheet structure:

Despite the high level of investment in the future in recent years, Biotest continues to have a very healthy and solid balance sheet structure. For example, we were able to improve our equity ratio from 31% at the end of 2022 to 35% at the end of 2023.

Chart 10, Cash flow:

When taking a brief look at the development of cash flow, I would particularly like to mention the improvement in cash flow from operating activities from € -41 million to € -3 million.

8

Chart 11, Separation page sustainability management:

This concludes my brief remarks on the key financial figures for the 2023 financial year and I would like to turn briefly to our unreserved commitment to sustainability.

We are proud of the fact that our business model is unique in terms of the utilisation of natural resources. Our most important resource, human blood plasma, is per se a "renewable resource" and inherently sustainable.

Nevertheless, in addition to our great responsibility towards our donors and patients, we are aware of our equally great responsibility towards our environment and future generations. With this in mind, Biotest has also set out to operate more sustainably and to produce in a way that conserves resources. We are aware of our responsibility as part of a sustainable society.

9

Chart 12, Linfa mural:

With the mural called "Linfa" on our car park, we are clearly demonstrating our commitment to more responsible corporate governance to all employees and our neighbours. It is not only an impressive work of art by international eco-artist Iena Cruz with a special air- purifying paint that neutralises as much CO2 from the air per year as around 100 trees, but also a promise for more sustainability in our corporate management. A promise for the future by which we will be measured.

Allow me to introduce the Go Future project to you in a short film:

Film is played.

10